Corona Remedies IPO Allotment Status: Check Latest GMP, Steps To Verify Status
The basis of allotment for the ₹655.37 crore Corona Remedies IPO will be announced today, 11 December 2025. Investors can check the IPO allotment status through the official websites of the NSE, BSE, or the IPO’s registrar, Bigshare Services.
Procedure to Check Corona Remedies IPO Allotment Status Online On NSE
- Visit the NSE’s IPO allotment verification status page here.
- Select “Equity & SME IPO bid details”.
- In Select Symbol, select “CORONA”.
- Enter your PAN No. and application No.
- Click “Submit”.
Procedure to Check Corona Remedies IPO Allotment Status Online On BSE
- Click here to visit the application status page.
- In Issue Type, “Equity”.
- In Issue Name, select “Corona Remedies LIMITED”.
- Enter your “Application No.” or “PAN No.”
- Click on “I am not a robot”.
- Click “Submit”.
Procedure to Check Corona Remedies IPO Allotment Status on Bigshare Services Private Limited (Registrar to the issue)
- Visit the Bigshare Services IPO allotment status page here.
- Click any of the server links.
- In Company Selection, select “Corona Remedies Limited”.
- Enter either your application number, beneficiary ID or PAN.
- Enter the captcha and click “Search”.
Corona Remedies IPO Overview
Corona Remedies IPO is a book-building issue of ₹655.37 crore, consisting entirely of an offer for sale (OFS) of 0.62 crore shares.
The bidding window was open from December 8, 2025, to December 10, 2025, during which the IPO received a total subscription of 137.04x. The price band is set between ₹1008 and ₹1062 per share.
Book-running lead managers for the IPO are JM Financial Limited, IIFL Capital Services Limited, and Kotak Mahindra Capital Company Limited, while Bigshare Services Private Limited (Link Intime) is the registrar for the IPO.
Corona Remedies IPO Overall Subscription Status
[10 December, 2025, End of the day]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
278.52 |
|
Non-Institutional Investors |
208.88 |
|
Retail Individual Investors (RIIs) |
28.73 |
|
Employees |
14.72 |
|
Total |
137.04 |
Corona Remedies IPO GMP
According to media reports, the Grey Market Premium (GMP) of the Corona Remedies IPO is reported at ₹270 over the IPO price.
Utilisation of IPO Proceeds
As the issue is entirely an offer for sale, the company will not receive any proceeds, and they will be allocated directly to selling shareholders.
Corona Remedies Business Overview
Corona Remedies is a pharmaceutical company engaged in the development, manufacturing, and marketing of branded formulations across key therapeutic categories, including women’s health, cardio-diabetes, pain and musculoskeletal care, urology, and a range of multispecialty segments.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here